Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20 , Pages S5-S13 , December 2006

Update on the MA.17 extended adjuvant trial

  • Paul Goss (Director, Breast Cancer Research, Massachusetts General Hospital Cancer Center; Co-Director, Breast Cancer Disease Program, DF/HCC)

      Affiliations

    • Corresponding Author InformationTel.: +1 617 724 3118; Fax: +1 617 724 3166.

References 

  1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  2. Fisher B, Jeong JH, Bryant J, et al. National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364:858–868
  3. Fletcher-Louis M, Ireland S. Onkos Study 48: Breast Cancer. Waltham, MA: Decision Resources Inc.; 2000;
  4. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology. 1996;14:2738–2746
  5. Hortobagyi GN, Kau S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?. Proc Am Soc Clin Oncol. 2004;23(23s):(abstract 585)
  6. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute. 2001;93:684–690
  7. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. The New England Journal of Medicine. 2003;348:2431–2442
  8. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology. 1998;16:453–461
  9. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Annals of Oncology. 1998;9:639–645
  10. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology. 2003;21:2101–2109
  11. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology. 2001;19:3808–3816
  12. Eiermann W, Paepke S, Appfelstaedt J, et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology. 2001;12:1527–1532
  13. Thürlimann B on behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine. 2005;353:2747–2757
  14. Hamilton A, Piccart M. The third-generation nonsteroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Annals of Oncology. 1999;10:377–384
  15. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. The New England Journal of Medicine. 2003;349:1793–1802
  16. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 2005;97:1262–1271
  17. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment. 2006;99:295–300
  18. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal of Clinical Oncology. 2005;23:619–629
  19. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Journal of Clinical Oncology. 2005;23:7512–7517
  20. Jakesz R, Jonat W, Gnant M, et al. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  21. Viale G, Regan M, Dell'Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 44)
  22. Goss P, Ingle J, Tu D. NCIC CTG MA17: updated analysis on disease free survival (DFS) according to estrogen receptor and progesterone receptor status of the primary tumor. Eur J Cancer Suppl. 2006;4:149;(abstract 350)
  23. Goss P MA.17 Collaborative Trialists. Post-unblinding analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo): updated results. Eur J Cancer Suppl. 2006;4:109;(abstract 209)
  24. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology. 2005;16:1569–1583
  25. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. Journal of the National Comprehensive Cancer Network. 2005;3:309–314
  26. Jakesz R, Samonigg H, Greil R, et al. ABCSG. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Journal of Clinical Oncology. 2005;23:10s;(abstract 527)
  27. Horwitz KB, McGuire WL. Specific progesterone receptors in human breast cancer. Steroids. 1975;25:497–505
  28. Paik S, Hartmann DP, Dickson RB, et al. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Research and Treatment. 1994;31:301–307
  29. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Journal of the National Cancer Institute. 2005;97:1254–1261
  30. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine. 2003;18:937–947
  31. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001;11:95–102

PII: S1521-690X(06)00081-9

doi: 10.1016/j.beem.2006.10.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20 , Pages S5-S13 , December 2006

Article Tools

* Image Usage & Resolution